₹1,474.3
▲ +29.76 +2.06%
29 Jul 2026
NSE Listed · Pharmaceuticals
Cipla Ltd. (CIPLA)
Volume: 21,92,262Avg Vol 1W: 24,28,450Avg Vol 1M: 14,19,22952W Range:₹1,165.7₹1,673
Key Ratios
Checked 1h agoMarket Cap₹1,19,101 Cr
Current Price₹1,474.3
Previous Close₹1,444.54
High / Low (52w)₹1,673 / ₹1,165.7
Volume21,92,262
Avg Vol (1W)24,28,450
Avg Vol (1M)14,19,229
Stock P/E214.6
Book Value₹426.24
Dividend Yield0.94%
ROE11.27%
ROA9.11%
Revenue (TTM)—
Revenue Growth2.23%
Profit Margin14%
Total Debt₹117 Cr
Shares Outstanding81 Cr
Face Value₹2
EPS (TTM)₹6.87
P/B3.46
Debt / Equity0.02
50 DMA₹1,415.34
200 DMA₹1,406.46
Day change+2.06%
Price Chart
₹1,474.3▼ 6.33% · 1Y
2025-07-292026-07-29
20-day avg volume: 13.8L shares
Pros
- Company is almost debt-free.
- Revenue grew 21% YoY.
- Net profit is growing year over year.
Cons
- Stock trades at a high P/E of 215.
Quarterly Results
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹7,051 Cr | ₹7,073 Cr | ₹6,730 Cr | ₹6,957 Cr | ₹7,589 Cr | ₹7,074 Cr | ₹6,541 Cr | ₹7,119 Cr |
| EBITDA | ₹1,804 Cr | ₹1,931 Cr | ₹1,518 Cr | ₹1,784 Cr | ₹1,867 Cr | ₹1,183 Cr | ₹720 Cr | ₹1,099 Cr |
| Net Profit | ₹1,303 Cr | ₹1,571 Cr | ₹1,222 Cr | ₹1,298 Cr | ₹1,351 Cr | ₹676 Cr | ₹555 Cr | ₹789 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹28,409 Cr | ₹4,798 Cr | ₹5,046 Cr | ₹5,226 Cr | ₹4,498 Cr | ₹4,210 Cr | ₹29,045 Cr | ₹5,078 Cr |
| EBITDA | ₹6,883 Cr | ₹1,464 Cr | ₹1,750 Cr | ₹1,636 Cr | ₹985 Cr | ₹529 Cr | ₹5,554 Cr | ₹1,159 Cr |
| Net Profit | ₹5,273 Cr | ₹1,485 Cr | ₹1,303 Cr | ₹1,211 Cr | ₹617 Cr | ₹385 Cr | ₹3,879 Cr | ₹862 Cr |
| EPS | 65.24 | — | — | — | — | — | 48 | — |
Balance Sheet
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹23,963 Cr | ₹23,663 Cr | ₹25,152 Cr | ₹27,101 Cr | ₹29,463 Cr | ₹32,718 Cr | ₹37,387 Cr | ₹42,496 Cr |
| Total Liabilities | ₹8,619 Cr | ₹7,605 Cr | ₹6,566 Cr | ₹5,984 Cr | ₹5,750 Cr | ₹5,915 Cr | ₹6,098 Cr | ₹7,976 Cr |
| Equity | ₹15,344 Cr | ₹16,057 Cr | ₹18,586 Cr | ₹21,117 Cr | ₹23,714 Cr | ₹26,802 Cr | ₹31,289 Cr | ₹34,520 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹2,284 Cr | ₹3,917 Cr | ₹4,793 Cr | ₹4,465 Cr | ₹4,540 Cr | ₹5,731 Cr | ₹6,673 Cr | ₹5,526 Cr |
| Investing | ₹-1,669 Cr | ₹104 Cr | ₹-2,387 Cr | ₹-1,872 Cr | ₹-2,389 Cr | ₹-2,988 Cr | ₹-3,691 Cr | ₹-2,326 Cr |
| Financing | ₹-349 Cr | ₹-2,949 Cr | ₹-1,240 Cr | ₹-1,600 Cr | ₹-958 Cr | ₹-1,200 Cr | ₹-1,293 Cr | ₹-1,234 Cr |
| Free Cash Flow | ₹2,284 Cr | ₹3,917 Cr | ₹4,793 Cr | ₹4,465 Cr | ₹4,540 Cr | ₹5,731 Cr | ₹6,673 Cr | ₹5,526 Cr |
Shareholding
Promoter 29.21% Institutions 54.84% Public 15.95%
Efficiency & Working Capital
ROCE13.9%
Interest Coverage97
Dividend Payout—
Debtor Days73 d
Inventory Days85 d
Payable Days42 d
Cash Conversion Cycle116 d
Working Capital Days158 d
Shareholding Details
As of 2026-06-30
Promoter29.2%
FII20.2%
DII34.6%
Institutions54.8%
Public15.9%
Promoter Pledge0%
No. of Shareholders5,78,679
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 33.5% | 33.5% | 33.5% | 30.9% | 30.9% | 29.2% | 29.2% | 29.2% | 29.2% | 29.2% | 29.2% | 29.2% |
| FIIs | 25.7% | 25.7% | 25.8% | 27.8% | 28.8% | 26.7% | 26.3% | 25.2% | 24.5% | 23.9% | 22.6% | 20.2% |
| DIIs | 24.2% | 24.3% | 24.4% | 24.9% | 24.2% | 27.7% | 28.2% | 29.3% | 30.2% | 30.7% | 32% | 34.6% |
| Public | 16.6% | 16.5% | 16.3% | 16.3% | 16.1% | 16.4% | 16.4% | 16.3% | 16% | 16.1% | 16.3% | 15.9% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 4,26,861 | 4,25,731 | 4,36,154 | 4,63,569 | 4,70,234 | 5,25,114 | 5,43,420 | 5,49,655 | 5,34,587 | 5,40,521 | 5,84,217 | 5,78,679 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202603 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Yusuf Khwaja Hamied | Shareholding of Promoter and Promoter Group | 18.7% | 15.05 Cr |
| Lici Ulip-growth Fund | Public Shareholding | 9.8% | 7.86 Cr |
| Sophie Ahmed | Shareholding of Promoter and Promoter Group | 5.7% | 4.60 Cr |
| Hdfc Trustee Company Limited-hdfc Flexi Cap Fund | Public Shareholding | 4.5% | 3.61 Cr |
| M K Hamied | Shareholding of Promoter and Promoter Group | 3.5% | 2.78 Cr |
| Sbi Nifty 50 Equal Weight Index Fund | Public Shareholding | 3.2% | 2.61 Cr |
| Icici Prudential Equity Savings Fund | Public Shareholding | 2.4% | 1.90 Cr |
| Nippon Life India Trustee Ltd-a/c Nippon India Arb | Public Shareholding | 2% | 1.58 Cr |
| Dsp Nifty 50 Index Fund | Public Shareholding | 1.9% | 1.53 Cr |
| Parag Parikh Arbitrage Fund | Public Shareholding | 1.9% | 1.51 Cr |
| Nps Trust A/c - Lic Pension Fund - Ups - Cg Schem | Public Shareholding | 1.7% | 1.37 Cr |
| Kamil Hamied | Shareholding of Promoter and Promoter Group | 1.4% | 1.09 Cr |
| Government Pension Fund Global | Public Shareholding | 1.3% | 1.04 Cr |
| Farida Hamied | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Samina Hamied | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Rumana Hamied | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Shirin Hamied | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Mn Rajkumar Garments Llp | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Shree Riddhi Chemicals Llp | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Alps Remedies Private Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Hamsons Laboratories Llp | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Okasa Pharma Private Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Healing Cross Pharma Private Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Nce Research Labs Private Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Uniworld Pharma Private Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Y K Hamied | Chairman & Non Executive Dir. | 2026 |
| P R Ramesh | Vice Chairman / Independent Non Executive Director | 2026 |
| Kamil Hamied | Non-Exec & Non-Independent Dir | 2026 |
| Abhijit J. Joshi | Non-Exec & Non-Independent Dir | 2026 |
| Adil Zainulbhai | Non-Exec & Non-Independent Dir | 2026 |
| Dr Balram Bhargava | Independent Non Exe. Director | 2026 |
| Mandar Purushottam Vaidya | Independent Non Exe. Director | 2026 |
| MAYA HARI | Independent Non Exe. Director | 2026 |
| SHARMILA NITIN PARANJPE | Independent Non Exe. Director | 2026 |
| Achin Gupta | MD / Global CEO / Global COO | 2026 |
| Rajendra Chopra | Company Sec. & Compli. Officer | 2026 |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| India | ₹10,116 Cr | 59.2% |
| Export sales | ₹6,978 Cr | 40.8% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2026 | ₹2 | 175 | 162 | 162 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-07-23 | Board Meetings | — |
| dividend | 2026-06-05 | ₹13.0 (650.0%) | Final |
| dividend | 2026-06-05 | ₹13 (650%) | Final |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2026 | 8,763 | 76 | 0 | 326 | 466 | 9,632 |
| 2026 | 1,237 | 0 | 0 | 0 | 0 | 1,237 |
| 2026 | 44 | 0 | 0 | 0 | 0 | 44 |
Insider / Designated-Person Trades
21 recent disclosure(s)
Anusha JainDisposal · 2,000
Anusha JainDisposal · 3,000
Priyanka MallickAcquisition · 200
Priyanka MallickAcquisition · 500
Jaideep MallickAcquisition · 150
Vidya Prabhakar Rote jointly with Kiran RoteRevoke · 1,000
Substantial Acquisitions (SAST)
5 disclosure(s)
Market17/07/2025 · 3,00,000
Market02/12/2024 · 1,38,98,000
Market24/07/2024 · 1,98,728
Market19/06/2024 · 23,573
Market15/05/2024 · 2,04,50,375
Company Information
Incorporated1935
ChairmanY K Hamied
AuditorB S R & Co LLP/Walker Chandiok & Co LLP
Investor Email[email protected], [email protected]
📍 Cipla House Peninsula Buss Par, Ganpatrao Kadam Mg Lower Parel, Mumbai, Maharashtra, 400013
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search